Clinical trials: Relapsed Lymphoblastic Leukemia
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00967057
- Testing
- asparaginase, dexamethasone, idarubicin
- Where
- 6 sites in Australia, United Kingdom
- Volunteers
- 470 people
- Sponsor
- Children's Cancer and Leukaemia Group
Lymphoma
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Interferon-alfa may interfere with the growth of cancer cells. Giving interferon-alfa following chemotherapy and peripheral stem cell transplantation may be an effective treatment for Hodgkin's disease or non-Hodgkin's…
- Trial name
- NCT00003924
- Testing
- recombinant interferon alfa
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 360 people
- Sponsor
- Lymphoma Study Association
Relapsed Acute Leukemia, Refractory Acute Leukemia
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Based on what is known about it's mechanism of action, bortezomib is presumed to make other chemotherapy drugs work better. This study examines the use of bortezomib in combination with an already effective chemotherapy regimen…
- Trial name
- NCT00410423
- Testing
- Bortezomib with mitoxantrone, etoposide and cytarabine, Bortezomib 1.0mg/m^2, Bortezomib 1.3mg/m^2
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lymphoblastic Leukemia, Acute Adult
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell…
- Trial name
- TBI-1501 (NCT03155191)
- Testing
- TBI-1501
- Where
- 11 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Takara Bio Inc.
Chronic Lymphocytic Leukemia
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with chronic lymphocytic leukemia who are relapsed after receiving prior treatment.
- Trial name
- NCT00108108
- Testing
- HCD122
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloproliferative Disorders, Leukemia
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients with stage III or stage…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002980
- Testing
- decitabine
- Where
- 4 sites in United States
- Sponsor
- California Cancer Consortium
Chronic Lymphocytic Leukemia
A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
This is an open-label phase I/II study that will investigate the combination of dasatinib and rituximab therapy in patients with relapsed/refractory CLL.
- Trial name
- BMS-CA180105 (NCT00949988)
- Testing
- Dasatinib and Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of California, San Diego
Anemia, Fatigue
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
This pilot clinical trial studies the side effects and best dose of metformin hydrochloride and ritonavir in treating patients with multiple myeloma or chronic lymphocytic leukemia that has returned after a period of improvement…
- Conditions
- Anemia, Fatigue, Fever, Lymphadenopathy
- Trial name
- NCT02948283
- Testing
- Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Leukemia
Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00083070
- Testing
- temozolomide
- Where
- 16 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule).
- Trial name
- NCT01585688
- Testing
- hLL1-DOX (IMMU-115)
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Gilead Sciences
Chronic Myeloproliferative Disorders, Fever, Sweats, and Hot Flashes
Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
RATIONALE: Antibiotics such as amoxicillin, ciprofloxacin, and moxifloxacin may be effective in preventing or controlling fever and neutropenia in patients with cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Fever, Sweats, and Hot Flashes, Infection, Leukemia
- Trial name
- NCT00062231
- Testing
- amoxicillin-clavulanate potassium, ciprofloxacin, moxifloxacin hydrochloride
- Where
- 23 sites in Belgium, France and 6 more
- Volunteers
- 351 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia, Lymphoma
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
RATIONALE: Giving low-dose total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00996359
- Testing
- Irradiated haploidentical allogeneic lymphocytes, total-body irradiation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
This randomized phase I trial is studying the side effects and best dose of two different schedules of sorafenib in treating patients with refractory or relapsed acute leukemia, myelodysplastic syndromes, or blastic phase chronic…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
- Trial name
- NCT00217646
- Testing
- Sorafenib Tosylate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
T Cell Lymphoma, T Cell Leukemia
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies.
- Conditions
- T Cell Lymphoma, T Cell Leukemia, T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoma of CNS
- Trial name
- BAH246 (NCT06420076)
- Testing
- CD5/CD7 CAR-T
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Essen Biotech
Acute Lymphocytic Leukemia
Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
Alemtuzumab is an anti CD52 monoclonal antibody. The CD52 antigen is present at the surface of B,T NK lymphocytes. It is expressed at various levels at the surface of ALL blast cells.
- Trial name
- Campath (NCT00773149)
- Testing
- Alemtuzumab (CAMPATH 1H) associated to G-CSF
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Recurrent Adult Acute Lymphoblastic Leukemia
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
This phase II trial is studying how well giving combination chemotherapy together with alemtuzumab works in treating patients with relapsed or refractory acute lymphoblastic leukemia.
- Trial name
- NCT00262925
- Testing
- alemtuzumab, asparaginase, methotrexate
- Where
- 58 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
B-Cell Pediatric ALL
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
The primary objective of this study is to evaluate the efficacy of moxetumomab pasudotox in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma.
- Trial name
- NCT02227108
- Testing
- Moxetumomab Pasudotox
- Where
- 21 sites in United States, Australia and 6 more
- Volunteers
- 37 people
- Sponsor
- MedImmune LLC
Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma
CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
Adult patients with refractory or relapsed CD123+ hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, or blastic plasmocytoid dentritic cell neoplasm will be…
- Conditions
- Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic Syndromes (MDS), Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Trial name
- UHKT-CAR123-01 (NCT06765876)
- Testing
- Autologous CAR123 T lymphocytes
- Where
- Czechia
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
Chronic Lymphocytic Leukemia
Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy
This is a phase I - II multicenter, non-comparative, open label study in patients with previously treated CLL aimed at defining the MTD of Lenalidomide given in combination with Fludarabine, Cyclophosphamide and at evaluating the…
- Trial name
- LLC0606 (NCT00727415)
- Testing
- Cyclophosphamide, Fludarabine phosphate, Lenalidomide
- Where
- 23 sites in Italy
- Volunteers
- 42 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto